Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Abroad (travel likely)RecruitingPHASE1
Conditions
Advanced Solid Tumor · Cutaneous Tumor · Subcutaneous Tumor · Malignant Solid Tumor · Solid Tumor · Metastatic Solid Tumor · Metastasis to Soft Tissue · Non Small Cell Lung Cancer · Cutaneous Squamous Cell Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
National Cancer Institute, Bethesda, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Providence Cancer Institute, Portland, Oregon, United States
Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Study leads
Joseph Elassal, MD, MBA
Study Director
Ankyra Therapeutics, Inc